Influence of chronic ischemic disorders in the prostate on the development of benign prostatic hyperplasia

Purpose of the study. To assess the degree of influence of ischemic disorders in the prostate on the level of androgens.

Materials and methods. This was an experimental study that included 20 white non-linear sexually Mature rats. All animals were divided into 2 equal groups: main and control (intact). In the main group of animals (n=10), we created a model of chronic ischemic disorders in the prostate by partial ligation of the inferior Vena cava. After 1.5 months, we conducted a hormonal study in all rats (n=20) — determining the concentration of androgens (testosterone, dihydrotestosterone) and estrogens (estradiol) in the blood of animals and prostate tissue.

Results. In the blood of animals of both groups, the level of total testosterone and estradiol did not significantly differ (p>0.05). The level of dihydrotestosterone in the blood serum of rats of the main group on the background of ischemia was reduced by 18.1%, compared to the intact group (p>0.05). However, we detected elevated levels of testosterone (p<0.05) and dihydrotestosterone (p>0.05) in prostate tissue against the background of chronic ischemia.

Conclusions. Chronic ischemic disorders in the prostate can be an independent pathogenetic factor in the development of BPH. Vascular damage leads to impaired blood flow and hypoxia, with increased tissue concentration of testosterone, which potentiates the development of BPH.

1. Xuan HN, Huy HD, Bich NNT, Hoang GP, Van KL, Duy TN, et al. Anatomical Characteristics and Variants of Prostatic Artery in Patients of Benign Hyperplasia Prostate by Digital Subtraction Angiography. Open Access Maced J Med Sci. 2019 Jul 13; 7(24): 4204–4208. https://doi.org/10.3889/oamjms.2019.361

2. Bortnick EM, Simma-Chiang V, Kaplan SA. Long-term Consequences of Medical Therapy for Benign Prostatic Hyperplasia. Rev Urol. 2019; 21(4): 154–157.

3. Chumakov PI, Marchenko LA, Kravchenko IV. Epidemiology of Age-Related Androgen Deficiency in Patients with Benign Prostatic Hyperplasia. RUDN Journal of Medicine. 2018; 22(3): 272–278. https://doi.org/10.22363/2313–0245–2018–22–3-272–278

4. Chekashkina VE, Strachuk AG. Prevention of benign prostatic hyperplasia. Bulletin “Biomedicine and sociology”. 2018; 3(4): 41–44. (In Russian).

5. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013; 112(4): 432–441. https://doi.org/10.1111/bju.12118

6. Astashov VV, Borodin YuI, Yurov MA, Larionov PM, Ivanova EB, Kazakov OV, et al. Blood and lymph circulation in the prostate in dyscirculatory disorders. Journal of Applied toxicology. 2012; 3(7): 27–35. (In Russian).

7. Kulchenko NG. Optimizing the conservative therapy of benign prostatic hyperplasia by inhibitors of 5–alfareductase. Clinical and morphological study. Kursk Scientific and Practical Bulletin “Man and His Health”. 2012; 1: 101–106. (In Russian).

8. Sudeep HV, Venkatakrishna K, Amrutharaj B, Anitha, Shyamprasad K. A phytosterol-enriched saw palmetto supercritical CO2 extract ameliorates testosterone-induced benign prostatic hyperplasia by regulating the inflammatory and apoptotic proteins in a rat model. BMC Complement Altern Med. 2019; 19(1): 270. https://doi.org/10.1186/s12906–019–2697-z

9. Akobova R1, Ryzhakin SM. Drug therapy of benign prostatic hyperplasia. Bulletin “Biomedicine and sociology”. 2019; 4(2): 21–24. (In Russian). https://doi.org/10.26787/nydha-2618–8783–2019–4-2–21–24

10. Kaprin AD, Kostin AA, Kulchenko NG. A relationship between ultrasound and morphological changes of prostate tissue in patients with benign hyperplasia during medical therapy. Andrology and Genital Surgery. 2012; 13(3): 47–51. (In Russian).

11. Danilov VV, Osinkin KS, Sevryukov FA. Reproducibility of uroflowmetry results in patients with benign prostatic hyperplasia. Questions of urology and andrology. 2019; 7(3): 5–9. (In Russian). https://doi.org/10.20953/2307–6631–2019–3-5–9

12. Roytberg G, Dorosh Z. Application of a holistic approach to assessing the risk of progression of atherosclerotic vascular disease in patients with insulin resistance by a general practitioner. General practitioner's guide. 2018; (5): 14–19. (In Russian).

13. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006; 98: 1038–1042.

14. Thurmond P, Yang JH, Li Y, Lerner LB, Azadzoi KM. Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia. Korean J Urol. 2015; 56(3): 187–96. https://doi.org/10.4111/kju.2015.56.3.187

15. Kirpatovskij VI, Mkrtchyan KG, Frolova EV, Kazachenko AV. The role of the hormonal factors and blood supply disturbances of the prostate in the pathogenesis of the benign prostatic hyperplasia. Experimental and Clinical Urology. 2013; 2: 38–45. (In Russian).

16. Hawkins P, Morton DB, Burman O, Dennison N, Honess P. A guide to defining and implementing protocols for the welfare assessment of laboratory animals: eleventh report of the BVAAWF/ FRAME/RSPCA/UFAW Joint Working Group on Refinement Westwood K National Research Council. Lab Anim. 2011; 45(1): 1–13. https://doi.org/10.1258/la.2010.010031

17. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013; 382(9901): 1329–1340.

18. Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003; 170(2): 659–663. https://doi.org/10,1097/01.ju.0000064923.29954.7e

19. Zarifpour M, Nomiya M, Sawada N, Andersson KE. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia. Prostate 2015; 75(3): 233–241. https://doi.org/10.1002/pros.22909

20. Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits.J. Urol. 2010; 165: 1019–1026.

21. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011; 82: 184–199.

22. Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, et al. NF-κB and androgen receptor variant expression correlate with human BPH progression. Prostate. 2016; 76(5): 491–511. https://doi.org/10.1002/pros.23140

23. Teichgräber U, Aschenbach R, Diamantis I, von Rundstedt FC, Grimm MO, Franiel T. Prostate Artery Embolization: Indication, Technique and Clinical Results. Rofo. 2018 Sep; 190(9): 847–855. https://doi.org/10.1055/a-0612–8067

24. Berger AP, Kofler K, Bektic J. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57: 57–65.